Takeda inks up to $600M AI drug-discovery deal with Insilico

Takeda Pharmaceutical has signed a collaboration with Insilico Medicine to apply artificial intelligence to early-stage drug discovery. The agreement gives Takeda exclusive worldwide rights to develop, manufacture and commercialise candidates discovered using Insilico’s platform.

Under the collaboration, Insilico will lead AI-driven discovery work using its Pharma.AI suite while Takeda will advance selected candidates through preclinical testing and clinical development and manage later-stage activities. The companies did not disclose which therapeutic areas or specific disease targets will be pursued.

The financial package includes roughly $60 million in upfront, near-term and project initiation payments. Additional milestone and sales-based payments tied to preclinical, clinical and commercial outcomes could raise the total to about $600 million. Insilico will also be eligible for tiered royalties on future product sales.

Insilico’s Pharma.AI suite supports target identification, de novo small-molecule generation and clinical trial prediction, functions the company groups under PandaOmics, Chemistry42 and InClinico.

Alex Zhavoronkov, Insilico’s founder and chief executive, noted that proceeds from the agreement will fund early-stage research under the collaboration and that later-stage timelines will depend on Takeda’s clinical development plans and coordinated work between the companies. Chris Arendt, Takeda’s chief scientific officer and head of research, said the pact pairs Takeda’s disease biology capabilities with Insilico’s AI tools and that Takeda is incorporating automation, robotics and generative AI into its discovery operations.

Insilico has previously advanced at least one AI-designed candidate into human testing: rentosertib (also ISM001-055), a small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis that reached a Phase 2a trial.

The agreement assigns discovery responsibilities to Insilico and later development responsibilities to Takeda. Progression of candidates into clinical trials will depend on conventional preclinical validation and Takeda’s clinical development schedule rather than the discovery timeline alone.

Insilico reported a string of recent collaboration agreements with large potential combined value. Takeda earlier this year agreed a multi-year AI drug-design collaboration with Iambic worth more than $1.7 billion focused on cancer and gastrointestinal disease targets. Insilico’s Hong Kong-listed shares rose after the announcement of the Takeda collaboration.